Increased risk of hyperkalaemia w/ aliskiren, K-salts, K-sparing diuretics, ACE inhibitors, ARB, NSAIDs, heparins, immunosuppressants (eg, ciclosporin or tacrolimus), trimethoprim, co-trimoxazole. Increased risk of severe anaphylactoid reactions w/ extracorporeal treatments. Increased risk of angioedema w/ sacubitril/valsartan, racecadotril, mTOR inhibitors eg, sirolimus, everolimus, temsirolimus; gliptins eg, linagliptin, saxagliptin, sitagliptin, vildagliptin. Increased antihypertensive effect & risk of orthostatic hypotension w/ imipramine-like antidepressants eg, TCAs, neuroleptics. Additive effect w/ IV amphotericin B, systemic gluco- & mineralocorticoids, tetracosactide, stimulant laxatives. Additive BP-lowering effect w/ other antihypertensives. Reduced antihypertensive effect w/ corticosteroids, tetracosactide; sympathomimetics. Reversible increased serum conc & toxicity of lithium. Increased antihypertensive effects w/ baclofen. Attenuated antihypertensive effects w/ NSAIDs eg, ASA, COX-2 inhibitors & non-selective NSAIDs. Increased risk of worsened renal function & CV morbidity & mortality w/ aliskiren. Higher frequency of hypotension, syncope, hyperkalaemia & worsened renal function w/ ARB. Increased risk of angioneurotic oedema w/ estramustine. Additive hyperkalaemic effect w/ K-sparing drugs eg, triamterene, amiloride; K-salts. Increased blood-glucose lowering effects w/ antidiabetics eg, insulin, oral hypoglycemics. Reduced hypotensive effects w/ non-K-sparing diuretics. Reduced BP w/ nitroglycerin & other nitrates or vasodilators. Increased risk of leucopenia w/ allopurinol, cytostatic or immunosuppressive agents, systemic corticosteroids or procainamide. Lethal ventricular fibrillation & CV collapse w/ dantrolene infusion. Increased bioavailability w/ grapefruit or grapefruit juice. Significant increased amlodipine exposure w/ CYP3A4 inhibitors eg, PIs, azole, antifungals, macrolides (eg, erythromycin or clarithromycin, verapamil, diltiazem). Increased risk of hypotension w/ clarithromycin. Varied amlodipine conc w/ strong CYP3A4 inducers eg, rifampicin, Hypericum perforatum
. Risk of hypokalaemia w/ Torsade de pointes-inducing drugs. Favoured toxic effects of cardiac glycosides. Increased incidence of hypersensitivity reactions to allopurinol. Enhanced hypotensive effects w/ anaesth. Vol depletion & risk of hypotension w/ thiazide or loop diuretics. Nitritoid reactions w/ injectable gold (Na aurothiomalate). Lactic acidosis due to metformin. Increased risk of acute renal insufficiency w/ high-dose iodinated contrast media. Increased Ca levels. Increased creatinine level w/ ciclosporin. Increased tacrolimus blood levels. Increased mTOR inhibitors exposure. Increased exposure to simvastatin.